- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01832675
Clinical Trial With Bupivacaine Lozenges as Local Anaesthesia Under Upper Gastrointestinal Endoscopy
New Bupivacaine Lozenge as Topical Anesthesia Compared to Lidocaine Pharyngeal Spray Before Upper Gastrointestinal Endoscopy in Unsedated Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The research group has previously conducted a clinical study with patients who underwent an UGE at the Department of Gastroenterology, Hvidovre University Hospital, Denmark, where the effect of a new lidocaine lozenge was compared to the lidocaine suspension that was used as standard treatment. The results showed that the lozenge increased the patient's acceptance of the gag reflexes, decreased the patient discomfort during UGE and thereby increased patient acceptance of the UGE. Furthermore, there was a significant improvement in assessment of taste and texture of the lozenge compared to the suspension. A study by Thanvi et al. has shown that it is difficult to obtain valid VAS scores when the patients are sedated, as it might cause amnesia and may impair the patient's ability to make an accurate assessment of the discomfort. Sedation were a limitation for the study conducted by the research group, because of impairment in the patients judgmental abilities. Furthermore a longer duration of the effect of the lozenge was requested. Therefore, the research group reformulated the lozenge and changed the active pharmaceutical ingredient (API) to bupivacaine. Bupivacaine is an amide as lidocaine, but has a longer anesthetic effect and is four times as potent as lidocaine. It would therefore be relevant to optimize the study design and perform a new clinical study with unsedated patients undergoing UGE, where the bupivacaine lozenge was tested.
The clinical study was performed in the private gastrointestinal (GI) clinic at Hvidovre, Denmark. Before the UGE was performed the patient was locally anesthetized in the pharynx with a lidocaine spray as a standard treatment.
The hypothesis was that a bupivacaine lozenge would reduce the patient experienced discomfort during UGE due to a better local anesthetic effect compared to lidocaine spray. Moreover it is hypothesized that the bupivacaine lozenge would be more patient friendly than the lidocaine spray because of a better taste masking according to lesser bitter taste and a pleasant mode of being anesthetized.
The aim of the study was to compare patient discomfort by two different local anesthetic methods. The standard treatment was a lidocaine pharyngeal spray and was compared to the experimental treatment a bupivacaine lozenge. The efficacy and acceptance of the treatments were also examined, as well as the taste of the anesthetics. Furthermore the patient's and endoscopist's assessment of the UGE was examined.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Hvidovre, Denmark, 2650
- Kirurgisk Klinik Hvidovre
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Referral from personal doctor for the upper gastroscopic endoscopy
- Age between 18 and 80 year
- Able to speak, read and understand the danish language
- Must be informed orally and released a written consent and a signed authorization statement
Exclusion Criteria:
- Known allergy to bupivacaine or other local anesthetics of the amide type.
- Pregnancy - the patient will be asked if she uses sufficient contraception. When in doubt a pregnancy test will be performed.
- Breastfeeding
- Use of other medicine before the examination besides the experimental medicine.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Bupivacaine lozenge
The patients will either get lidocaine spray or bupivacaine lozenge as an anaesthetic drug before the upper gastroscopic endoscopy.
|
25 mg bupivacaine/lozenge.
The patient will get one lozenge 10-15 minutes before the examination.
|
Active Comparator: Xylocain, cutaneous spray, solution
The patients will either get lidocaine spray or bupivacaine lozenge as an anaesthetic drug before the upper gastroscopic endoscopy.
|
10 mg lidocaine/spray.
The patient will be sprayed three times and get a maximal dose of 30 mg lidocaine just before the examination.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The patient experienced discomfort assessed on the Visual Analog Scale
Time Frame: Day 1
|
The patient experienced discomfort during a upper gastroscopic endoscopy when using bupivacaine lozenge instead of lidocaine spray assessed on the Visual Analog Scale
|
Day 1
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient evaluation of taste and texture on a 3 point scale. - The investigator's assessment of the study by answering the questionnaire.
Time Frame: Day 1
|
Patient evaluation of taste and texture of the lozenge or the spray on a 3 point scale.
|
Day 1
|
Endoscopist evaluation on a 4 point scale.
Time Frame: Day 1
|
The endoscopist evaluate the difficulty of the upper gastrointestinal endoscopy on a 4 point scale.
|
Day 1
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kaare Nielsen, MD, Kirurgisk Klinik Hvidovre
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2011-0056-22-21
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Application Site Discomfort
-
University of North Carolina, Chapel HillCompletedMedical Device Discomfort | Application Site DiscomfortUnited States
-
Gaziantep Islam Science and Technology UniversityRecruitingApplication Site DiscomfortTurkey
-
Larkin Community HospitalGeorge Mason UniversityWithdrawn
-
West China HospitalUnknownCatheter Site DiscomfortChina
-
West China HospitalUnknownCatheter Site DiscomfortChina
-
Washington University School of MedicineTerminatedCatheter Site Discomfort | Urethra InjuryUnited States
-
Sakarya UniversityCompletedApplication Site InfectionTurkey
-
Saglik Bilimleri UniversitesiCompleted
-
Eskisehir Osmangazi UniversityRecruiting
-
Vander Haegen MarieWithdrawn
Clinical Trials on Bupivacaine lozenge
-
Novozymes A/SUniversity of AarhusTerminated
-
Rock Creek Pharmaceuticals, Inc.CompletedSmoking | Tobacco Use DisorderUnited States
-
Novozymes A/SCompleted
-
Novozymes A/SUniversity of AarhusCompletedGingivitis | Microbial Colonization | Dental PlaqueDenmark
-
Northwestern UniversityEnrolling by invitation
-
Novozymes A/SUniversity of AarhusRecruitingDental Biofilm AccumulationDenmark
-
Johns Hopkins UniversityTerminatedUrologic Diseases | Hypospadias | Hydrocele | Undescended Testes | Orchiectomy | ChordeeUnited States
-
University of North Carolina, Chapel HillNational Institute of Dental and Craniofacial Research (NIDCR)Completed
-
Bitop AGCompleted